Asian drug stocks faced a downturn. This followed US President Trump’s tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumitomo Pharma saw significant drops. Celltrion bucked the trend with a slight gain. Experts suggest limited broader economic impact. The US government’s tariff rate is expected to rise.